Ifetroban

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ifetroban
Accession Number
DB12321
Type
Small Molecule
Groups
Investigational
Description

Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
BMS-180291
Product Ingredients
IngredientUNIICASInChI Key
Ifetroban Sodium48IJA0E92C156715-37-6WOHSQDNIXPEQAE-QBKVZTCDSA-M
Categories
UNII
E833KT807K
CAS number
143443-90-7
Weight
Average: 440.54
Monoisotopic: 440.231122138
Chemical Formula
C25H32N2O5
InChI Key
BBPRUNPUJIUXSE-DXKRWKNPSA-N
InChI
InChI=1S/C25H32N2O5/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29)/t18-,20-,21+,23-/m0/s1
IUPAC Name
3-(2-{[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl}phenyl)propanoic acid
SMILES
CCCCCNC(=O)C1=COC(=N1)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1CC1=CC=CC=C1CCC(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabIfetroban may increase the anticoagulant activities of Abciximab.
AcenocoumarolThe risk or severity of bleeding can be increased when Ifetroban is combined with Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ifetroban is combined with Acetylsalicylic acid.
AloxiprinThe risk or severity of adverse effects can be increased when Ifetroban is combined with Aloxiprin.
AlteplaseIfetroban may increase the anticoagulant activities of Alteplase.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Ifetroban is combined with Aminosalicylic Acid.
AnagrelideIfetroban may increase the anticoagulant activities of Anagrelide.
AncrodIfetroban may increase the anticoagulant activities of Ancrod.
AndrographolideAndrographolide may increase the antiplatelet activities of Ifetroban.
AnistreplaseIfetroban may increase the anticoagulant activities of Anistreplase.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
3037233
PubChem Substance
347828584
ChemSpider
16736637
ChEMBL
CHEMBL3301673
Wikipedia
Ifetroban

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAspirin Exacerbated Respiratory Disease (AERD)1
2CompletedTreatmentHepatorenal Syndrome1
2CompletedTreatmentLiver Cirrhosis / Portal Hypertension1
2Not Yet RecruitingTreatmentAdenocarcinoma of the Pancreas / Anatomic Stage II Breast Cancer / Anatomic Stage IIA Breast Cancer / Anatomic Stage IIB Breast Cancer / Anatomic Stage III Breast Cancer / Anatomic Stage IIIA Breast Cancer / Anatomic Stage IIIB Breast Cancer / Anatomic Stage IIIC Breast Cancer / Clinical Stage II Esophageal Adenocarcinoma / Clinical Stage II Esophageal Squamous Cell Carcinoma / Clinical Stage II Gastric Cancer / Clinical Stage II Gastroesophageal Junction Adenocarcinoma / Clinical Stage IIA Esophageal Adenocarcinoma / Clinical Stage IIA Gastric Cancer / Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma / Clinical Stage IIB Esophageal Adenocarcinoma / Clinical Stage IIB Gastric Cancer / Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma / Clinical Stage III Esophageal Adenocarcinoma / Clinical Stage III Esophageal Squamous Cell Carcinoma / Clinical Stage III Gastric Cancer / Clinical Stage III Gastroesophageal Junction Adenocarcinoma / Distal Esophagus Squamous Cell Carcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Limited Stage Small Cell Lung Carcinoma / Malignant Solid Neoplasm / Non-Small Cell Lung Carcinoma (NSCLC) / Oesophageal Carcinoma / Pathologic Stage II Esophageal Adenocarcinoma / Pathologic Stage II Esophageal Squamous Cell Carcinoma / Pathologic Stage II Gastric Cancer / Pathologic Stage II Gastroesophageal Junction Adenocarcinoma / Pathologic Stage IIA Esophageal Adenocarcinoma / Pathologic Stage IIA Esophageal Squamous Cell Carcinoma / Pathologic Stage IIA Gastric Cancer / Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma / Pathologic Stage IIB Esophageal Adenocarcinoma / Pathologic Stage IIB Esophageal Squamous Cell Carcinoma / Pathologic Stage IIB Gastric Cancer / Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma / Pathologic Stage III Esophageal Adenocarcinoma / Pathologic Stage III Esophageal Squamous Cell Carcinoma / Pathologic Stage III Gastric Cancer / Pathologic Stage III Gastroesophageal Junction Adenocarcinoma / Pathologic Stage IIIA Esophageal Adenocarcinoma / Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma / Pathologic Stage IIIA Gastric Cancer / Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma / Pathologic Stage IIIB Esophageal Adenocarcinoma / Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma / Pathologic Stage IIIB Gastric Cancer / Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma / Pathologic Stage IIIC Gastric Cancer / Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma / Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma / Postneoadjuvant Therapy Stage II Gastric Cancer / Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma / Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma / Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma / Postneoadjuvant Therapy Stage III Gastric Cancer / Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma / Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma / Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma / Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma / Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma / Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma / Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma / Progesterone Receptor Negative / Prognostic Stage II Breast Cancer / Prognostic Stage IIA Breast Cancer / Prognostic Stage IIB Breast Cancer / Prognostic Stage III Breast Cancer / Prognostic Stage IIIA Breast Cancer / Prognostic Stage IIIB Breast Cancer / Prognostic Stage IIIC Breast Cancer / Stage I Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage II Lung Cancer / Stage II Pancreatic Cancer / Stage IIA Lung Cancer / Stage IIA Pancreatic Cancer / Stage IIB Lung Cancer / Stage IIB Pancreatic Cancer / Stage III Lung Cancer / Stage IIIA Lung Cancer / Stage IIIb Lung Cancer / Stage IIIC Lung Cancer / Triple-Negative Breast Carcinoma1
2Not Yet RecruitingTreatmentAspirin-exacerbated Respiratory Disease / Aspirin-sensitive Asthma With Nasal Polyps / Asthma, Aspirin-Induced / Polyps, Nasal1
2Not Yet RecruitingTreatmentDuchenne Muscular Dystrophy Cardiomyopathy / Duchenne's Muscular Dystrophy (DMD) / Muscular Diseases / Muscular Dystrophy / Muscular Dystrophy, Duchenne1
2RecruitingTreatmentAsthma, Aspirin-Induced1
2RecruitingTreatmentAutoimmune Diseases / Connective Tissue Diseases / Diffuse Systemic Sclerosis / Pathologic Processes / Scleroderma, Limited / Scleroderma, Systemic / Sclerosis, Progressive Systemic / Skin Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0146 mg/mLALOGPS
logP4ALOGPS
logP3.95ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)4.65ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.66 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity119.24 m3·mol-1ChemAxon
Polarizability48.95 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
2-heteroaryl carboxamides / 2,4-disubstituted oxazoles / Benzene and substituted derivatives / Oxolanes / Heteroaromatic compounds / Secondary carboxylic acid amides / Oxacyclic compounds / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids
show 5 more
Substituents
3-phenylpropanoic-acid / 2-heteroaryl carboxamide / 2,4-disubstituted 1,3-oxazole / Monocyclic benzene moiety / Benzenoid / Azole / Heteroaromatic compound / Oxazole / Oxolane / Carboxamide group
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:57 / Updated on October 01, 2018 16:48